In this article, we review recent findings related to estrogen exposure and the risk of breast cancer, the mechanisms that may be involved, and the clinical implications of these findings. The weight of evidence indicates that exposure to estrogen is an important determinant of the risk of breast cancer. The mechanisms of carcinogenesis in the breast caused by estrogen include the metabolism of estrogen to genotoxic, mutagenic metabolites and the stimulation of tissue growth. Together, these processes cause initiation, promotion, and progression of carcinogenesis. Insight into the mechanisms of the causation of cancer by estrogen will identify determinants of susceptibility to breast cancer and new targets for prevention and therapeutic intervention.

An association between the risk of breast cancer and persistently elevated blood levels of estrogen has been found consistently in many studies. Several endocrine-associated risk factors are regularly associated with an increased relative risk of breast cancer in postmenopausal women. One of these factors is obesity, which is probably related to an increased production of estrogen by aromatase activity in breast adipose tissue. Another factor is an elevated blood level of endogenous estrogen (relative risk, 2.00 to 2.58). An increased relative risk is also associated with higher-than-normal blood levels of androstenedione and testosterone, androgens that can be directly converted by aromatase to the estrogens estrone and estradiol, respectively. Elevated urinary levels of estrogens and androgens are also associated with an increased risk of breast cancer in postmenopausal women. The level of serum progesterone has not been associated with a risk of breast cancer in postmenopausal women, whereas in premenopausal women, blood levels of progesterone appear to be inversely associated with the risk of breast cancer. All this evidence supports the hypothesis that cumulative, excessive exposure to endogenous estrogen across a woman’s life span contributes to and may be a causal factor in breast cancer.

Observational epidemiologic studies and a randomized clinical trial have investigated the long-term effects of replacement therapy—with estrogen alone (estrogen-replacement therapy) or with estrogen plus progestin (hormone-replacement therapy)—on various health outcomes, including breast cancer. In the United States, the main replacement preparations contain conjugated estrone plus various conjugated equine estrogens alone or combined with medroxyprogesterone acetate. A meta-analysis of data from 51 observational studies involving more than 160,000 women determined that for users of hormone- or estrogen-replacement therapy for 5 years or longer (average duration of use, 11 years), the relative risk was 1.35 (95 percent confi-
dence interval, 1.21 to 1.49). The hormone composition of the hormone-replacement therapy preparations was known for 39 percent of these women, and the risk of the use of hormone- or estrogen-replacement therapy was increased to a similar degree with each of the preparations. Risk was increased in current users and those who had stopped one to four years before diagnosis but not in those who had stopped five or more years before diagnosis — suggesting that the effect of hormone- or estrogen-replacement therapy may be reversible.

A recent observational study of more than 54,000 French women showed a similar statistically significant increase in risk (relative risk, 1.4; 95 percent confidence interval, 1.2 to 1.7) for women using hormone-replacement therapy but not estrogen-replacement therapy. In the Million Women observational study of unselected women in the United Kingdom recruited between 1996 and 2001, the relative risk of breast cancer was significantly elevated by the use of hormone- or estrogen-replacement therapy and increased with the duration of use. However, the risk was higher than those reported in other studies. Within a year after the cessation of use, the relative risk returned to that of patients who had never received replacement therapy, again suggesting that the effects of such therapy are reversible. Although a strength of this study was its large size, it had important weaknesses, including reliance on a single questionnaire and an enrollment bias that may have inflated the relative risks. Nevertheless, the results from all these observational studies, when taken together, suggest that ongoing or recent hormone-replacement therapy is associated with a small but significant increase in the risk of breast cancer (albeit reversible) and that estrogen replacement may have similar effects.

This question was tested in the Women’s Health Initiative study, a prospective trial in which postmenopausal women were randomly assigned to receive placebo or hormone-replacement therapy (if they had a uterus) or either placebo or estrogen-replacement therapy (if they had undergone hysterectomy). The study was terminated for both groups after a median follow-up of about five years because of the increased incidence of breast cancer, stroke, coronary heart disease, and pulmonary embolism in the group receiving hormone-replacement therapy and increased incidence of stroke and pulmonary embolism in the group receiving estrogen-replacement therapy, as compared with placebo. In the group receiving hormone-replacement therapy, the risk of breast cancer, expressed as the hazard ratio, was significantly increased. These results confirm the increased risk of hormone-replacement therapy observed in the Collaborative Group meta-analysis, the recent European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study, and the Million Women study, although the extent of the increase as represented by the hazard ratio cannot be compared directly with the increase represented by the relative risk. However, unlike the Collaborative Group meta-analysis and the Million Women study, the Women’s Health Initiative study found no increased risk of breast cancer in the group receiving estrogen-replacement therapy, whose members had undergone hysterectomy. Finally, the use of oral contraceptives is also associated with a small but significant increase in the risk of breast cancer during the time of use.

Why hormone-replacement therapy and estrogen-replacement therapy may have different influences on the risk of breast cancer is not clear. It is not unexpected that the combination of estrogen and progestin increases the risk of breast cancer, since progestins tend to increase cell proliferation in breast tissue and have a variety of other effects on the breast. Medroxyprogesterone acetate alone increases the incidence of mammary tumors in mice and dogs, but it was not associated with a significant increase in the relative risk of breast cancer, and endogenous progestin levels were not associated with an increased risk of breast cancer in women who used the drug as a contraceptive. Collectively, the results of epidemiologic studies of endogenous steroid hormone levels and the use of exogenous estrogen support the hypothesis that estrogen contributes to and may have a causal role in breast cancer, although the contribution to breast cancer of progestin associated with hormone-replacement therapy requires additional investigation.
in various tissues, including the kidneys, liver, uterus, and mammary glands.\textsuperscript{1,25-31} Figure 1 outlines two different but complementary pathways that together are likely to contribute to the carcinogenicity of estrogen.

\textbf{ESTROGEN METABOLISM}

Figure 2 shows estrogen metabolism through the catechol pathway. Phase I metabolism in humans, hamsters, mice, and rats involves several cytochrome P-450 enzymes that catalyze the oxidative metabolism of estrone and estradiol predominantly to a 2-hydroxycatechol estrogen (cytochrome P-450 1A1, 1A2, and 3A) or to 4-hydroxycatechol estrogen (cytochrome P-450 1B1).\textsuperscript{35} Cytochrome P-450 1B1 is constitutively expressed in the breasts, ovaries, adrenal glands, and uterus, as well as in several other tissues.\textsuperscript{33,36} The estrogen 3,4-quinone can form unstable adducts with adenine and guanine in DNA, leading to depurination and mutation in vitro and in vivo.\textsuperscript{32,37-39} Reduction of estrogen quinones back to hydroquinones and catechols provides an opportunity for redox cycling to produce reactive oxygen species\textsuperscript{32,34} and probably accounts for the oxidative damage to lipids and DNA that is associated with estrogen treatment.\textsuperscript{30,32,34,40-46}
damage caused by reactive metabolites of endogenous and exogenous chemicals. Figure 2 shows where catechol estrogen methylation catalyzed by catechol O-methyltransferase and estrogen semiquinone and quinone reaction with glutathione can occur. In addition to preventing metabolism of catechol estrogen to quinones, the 2-methoxy catechol may be a protective metabolite. Of interest, 4-hydroxyequilenin, a reactive catechol metabolite of equilenin, an equine estrogen present in hormone-replacement-therapy preparations, can inhibit detoxication enzymes such as glutathione S-transferase P1-1 and catechol O-methyltransferase. Furthermore, recombinant catechol O-methyltransferase with low activity was found to be more sensitive than the native enzyme to inhibition by 4-hydroxyequilenin. This suggests that reactive equine estrogen metabolites contribute to breast cancer through inhibition of protective phase II enzymes and raises the possibility that women who are homozygous for the polymorphic variant of catechol O-methyltransferase with a low activity could be at further increased risk when using hormone-replacement-therapy preparations containing equine estrogen.

Table 1 presents a selected summary of the biologic effects of treatment of cultured cells and experimental animals with estradiol or its metabolites. These observations support the hypothesis that oxidative metabolites of estrogen have genotoxic, mutagenic, transforming, and carcinogenic potential and thus could initiate or cause the progression of the carcinogenic process in humans. However, to date, no studies have definitively demonstrated that estrogen metabolites contribute to human breast cancer, although two lines of evidence support this possibility. First, the hypothesis that potentially genotoxic estrogen metabolites contribute to human breast cancer depends on their formation and presence in breast tissue. In postmenopausal women, estrogen levels in breast tissue are 10 to 50 times the levels in blood, and concentrations of estradiol were higher in malignant tissues than in nonmalignant tissues, a finding that...
probably reflects aromatase activity in breast tissue. Furthermore, levels of estrogen metabolites and conjugates ranging from 3 to 13 pmol per gram of tissue were detected in human breast tissue, demonstrating that the oxidative pathways shown in Figure 3 are active in human breast tissue. However, larger studies are needed to confirm these findings. It will be necessary to detect estrogen–quinone adenine and guanine adducts and oxidative DNA damage in human breast tissue to provide definitive evidence for estrogen genotoxicity that could contribute to the initiation or progression of breast cancer.

The second line of evidence supporting a role for estrogen metabolites in human breast cancer comes from studies of associations of breast-cancer risk and polymorphisms in genes encoding enzymes involved in estrogen synthesis and metabolism (Table 2). The products of these genes are involved in estrogen synthesis (e.g., cytochrome P-450 17 and cytochrome P-450 19; the latter is also called aromatase), aspects of phase I metabolism that might lead to increased levels of metabolites (e.g., cytochrome P-450 1A1 and cytochrome P-450 1B1), and actions of phase II metabolism that might lead to reduced protective conjugation (e.g., glutathione S-transferase M1 and catechol O-methyltransferase). Overall, the results of these studies have been inconsistent.

Such mixed results probably reflect the small size of the studies and the low penetrance of mutations in genes in these multigenic pathways. A typical example is represented by the studies on catechol O-methyltransferase. After the initial report of the association of homozygosity for an allele encoding a low-activity form of the enzyme with an increased risk of breast cancer (odds ratio for postmenopausal women, 2.2; 95 percent confidence interval, 0.9 to 5.2; odds ratio for postmenopausal women with a body-mass index [the weight in kilograms divided by the square of the height in meters] ≥24.5, 3.6; 95 percent confidence interval, 1.1 to 12), at least 10 subsequent studies explored this issue. Approximately half the studies detected an association, some in premenopausal women and some in postmenopausal women. A recent study observed combined effects of several reproductive factors and variant alleles for catechol O-methyltransferase and the glutathione S-transferases M1 and T1 with an increased risk of breast cancer. However, because the number of subjects of cases and controls in the combined groups was small, this finding requires independent confirmation. Ritchie et al. explored the association of combinations of 10 single-nucleotide polymorphisms in catechol O-methyltransferase, cytochrome P-450 1A1 and 1B1, and glutathione S-transferases M1 and T1 with the risk of breast cancer and observed that an interaction among the low-activity variant of catechol O-methyltransferase, two variants of

<table>
<thead>
<tr>
<th>Effect</th>
<th>Cell and Animal Model Systems</th>
</tr>
</thead>
</table>
| Estrogen 3,4-quinone DNA adducts and depurination | Kidney tissue in the male Syrian golden hamster<sup>37</sup> Mammary tissue in the ACI rat<sup>36</sup>
|                     | Skin tissue in the SENCAR mouse<sup>39</sup>                                                   |
| Oxidative DNA damage                        | Oxidative DNA damage in estrogen-treated MCF-7 cells<sup>40-43</sup>                         |
| Gene mutation                               | H<sub>prt</sub> gene in V79 cells<sup>57</sup> Thymidine kinase gene in MCF-7 cells<sup>58</sup>
|                     | H-ras gene in SENCAR mouse skin<sup>39</sup>                                                  |
| Neoplastic transformation                   | Transformation and genotoxicity in Syrian hamster embryo cells<sup>59-61</sup>                |
|                     | Estrogen-treated nontumorigenic human breast cell line MCF-10F<sup>62</sup>                   |
| Tumor development                           | Uterine tumors in 4-hydroxyestradiol and estrogen-treated CD-1 mice<sup>63</sup>               |
|                     | Mammary tumors in estrogen-treated ACI rats<sup>28,29</sup>                                   |
|                     | Kidney tumors in 4-hydroxyestradiol, 2-hydroxyestradiol, and estrogen-treated Syrian hamsters<sup>50,51</sup> |

<sup>a</sup> ACI denotes a cross between August and Copenhagen–Irish strains and SENCAR sensitive to carcinogenesis.
cytochrome P-450 1B1, and a variant of cytochrome P-450 1A1 were significantly associated with an increased risk of breast cancer, although these findings too require independent confirmation. Future efforts to determine whether polymorphisms that alter the expression or activities of genes that encode estrogen-metabolism enzymes influence susceptibility to breast cancer will require an assessment of their association with estrogen metabolite levels in breast tissue or secretions from both case subjects and control subjects.

**ESTROGEN-RECEPTOR SIGNALING**

Figure 3 summarizes the multiple estrogen-receptor signal-transduction pathways, emphasizing effects associated with increased proliferation and inhibition of apoptosis. Table 3 lists selected examples of signaling events mediated by estrogen receptors.

The classic mechanism of direct action of estrogen on nuclear DNA involves the binding of the hormone to nuclear estrogen receptors, which then bind as dimers to estrogen-response elements in the regulatory regions of estrogen-responsive genes and associate with basal transcription factors, co-activators, and corepressors to alter gene expression. Since the initial discovery and characterization of the estrogen receptor α (ERα) in the 1960s, research on mechanisms of estrogen-receptor signaling has revealed its complexity, as represented by the discovery of estrogen receptor β (ERβ) and
of signaling pathways mediated by estrogen receptors that become associated with mitochondria and the plasma membrane.\textsuperscript{78,86-89}

ER\textsubscript{\alpha} and ER\textsubscript{\beta} have 96 percent amino-acid identity in their DNA-binding domains, whereas there is only 53 percent homology in their ligand-binding domains; the latter accounts for differences in the responses of the two receptors to various ligands. For example, tamoxifen has been reported to be both an agonist and an antagonist for ER\textsubscript{\alpha} but only an antagonist for ER\textsubscript{\beta}. Also, ER\textsubscript{\beta} has a greater affinity for various phytoestrogens, such as genistein, than does ER\textsubscript{\alpha}.\textsuperscript{90} The receptors also differ in their activation domains, suggesting that they may recruit different proteins to the transcription complexes, thereby altering the specificity of their genomic transcriptional effects. Furthermore, estrogen receptors interact with coactivator proteins to stimulate the activity of other transcription factors, such as AP-1 (Table 3). Finally, various tyrosine kinase growth-factor receptors can activate estrogen receptors by phosphorylation in the absence of ligand (Table 3).

The presence of specific, high-affinity estrogen binding in nonnuclear subcellular fractions, including plasma membrane and mitochondria, implies that the estrogen receptor could be located at these sites.\textsuperscript{86,91} Indeed, recent studies have definitively shown the presence of ER\textsubscript{\alpha}, ER\textsubscript{\beta}, or both in mitochondria of various cells and tissues.\textsuperscript{75,92-96} The mitochondrial genome contains potentially estrogen-responsive sequences,\textsuperscript{76,77} and estrogen has increased mitochondrial DNA-encoded gene transcript levels (Table 3). The mechanisms of mitochondrial estrogen-receptor import are not known, although ER\textsubscript{\beta} contains a putative mitochondrial-targeting peptide domain.\textsuperscript{75} Studies are needed to elucidate the mechanisms of estrogen-receptor import, to determine how it functions to increase transcription of mitochondrial DNA, and to determine the role of the process in the response to estrogen.

Like peptide growth factors, estrogens also cause

| Table 2. Functional Effects of Selected Polymorphisms in Selected Estrogen Synthesis and Metabolizing Genes Associated with an Increased Risk of Breast Cancer.\textsuperscript{\textdagger} |
|---|---|---|---|
| Enzyme | Polymorphism | Functional Effect | Risk of Breast Cancer |
| Estrogen biosynthesis | | | |
| CYP 17 | A2 allele; T to C at position 1931 in gene-promoter region | May increase expression but is associated with increased levels of serum estrogen and progesterone | Increased risk in some studies, but finding not consistent |
| CYP 19 | (TTTA)\textsubscript{7-13} repeats | May alter mRNA splicing | Increased risk related to the number of repeats observed in several studies |
| Phase I enzyme | | | |
| CYP1A1 | \textsuperscript{\circ}2A allele; 3' of polyadenylation site | May increase activity | No increased risk in whites but increased risk observed in smokers and in Chinese and black women |
| | \textsuperscript{\circ}2C Ile\textsuperscript{462}Val allele | May increase activity | No increased risk in whites, but increased risk when serum PCB levels elevated |
| CYP1B1 | Val\textsuperscript{412}Leu allele | Increases activity of Val allele | Increased risk in some studies, but finding not consistent |
| Phase II enzyme | | | |
| GSTM1 | GSTM1 null | Removes activity | Increased risk in some studies, but finding not consistent |
| COMT | Val\textsuperscript{108/118}Met | Reduces activity of Met allele | Increased risk in some studies, but finding not consistent |

\textsuperscript{\textdagger} Data are from Mitrunen and Hirvonen,\textsuperscript{66} Ritchie et al.,\textsuperscript{67} and Miyoshi and Noguchi.\textsuperscript{68} CYP denotes cytochrome P-450, GSTM1 glutathione S-transferase M1, COMT catechol O-methyltransferase, and PCB polychlorinated biphenol.
activation of various protein kinases, such as mitogen-activated protein kinases, and increase levels of second messengers, such as cyclic AMP (cAMP), within minutes (Table 3). These nongenomic, nontranscriptional effects involve a membrane-bound form of ERα, ERβ, or both and facilitate cross-talk between the membrane estrogen-receptor–signaling process and other signal-transduction pathways, such as the epidermal growth factor receptor and insulin-like growth factor 1 receptor–signaling pathways (Fig. 3).73,74,97 Cross-talk between the genomic and second-messenger pathways probably has important roles in estrogenic control of cell proliferation and inhibition of apoptosis and may have implications for therapy.73,78,79,86,87,98

Catechol estrogen metabolites may also participate in the regulation of pathways of gene expression, signaling, or both through the estrogen receptor. The 4-hydroxycatechol and 2-hydroxycatechol estrogens have high binding affinities to the human estrogen receptor (150 percent and 100 percent, respectively, as compared with estradiol)99 and induce estrogen-receptor–dependent gene expression.100-102 Furthermore, a high-affinity, saturable, cytosolic binding protein for 4-hydroxyestradiol may be a novel receptor that mediates ERα- and ERβ-independent effects of the catechol estrogens.103 Determination of the effects of the catechol metabolites on the proliferation of human breast tissue and apoptosis deserves additional research.

Together, these new insights into multiple genomic and nongenomic estrogen-signaling pathways greatly expand our understanding of the potential cross-talk among various signal-transduction pathways. However, a thorough investigation is required of all the interacting signaling pathways mediated through the estrogen receptor and growth factors, such as epidermal growth factor and insulin-like growth factor 1, that function in human breast tissue in normal and tumor cells. This could facilitate the goal of achieving a comprehensive understanding of the control of proliferation and apoptosis by estrogen and its metabolites and perhaps reveal new targets for combined therapeutic intervention.

Table 3. Estrogen-Receptor–Mediated Signaling Pathways.*

<table>
<thead>
<tr>
<th>Pathway</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nuclear genomic DNA-encoded genes</td>
<td>Ligand-dependent, estrogen-receptor–mediated activation of genes controlled by estrogen-response-element sequences</td>
</tr>
<tr>
<td></td>
<td>Ligand-dependent estrogen-receptor interaction with other transcription factors71.72</td>
</tr>
<tr>
<td></td>
<td>Ligand-independent activation by estrogen-receptor phosphorylation mediated through other pathways73,74</td>
</tr>
<tr>
<td></td>
<td>EGF (or ErbB)</td>
</tr>
<tr>
<td></td>
<td>IGF-1</td>
</tr>
<tr>
<td></td>
<td>MAPK</td>
</tr>
<tr>
<td></td>
<td>PI3K–Akt</td>
</tr>
<tr>
<td>Mitochondrial genomic DNA-encoded genes</td>
<td>Ligand-dependent, estrogen-receptor–mediated activation of mitochondrial DNA–encoded genes controlled by estrogen-response-element–like sequences75-77</td>
</tr>
<tr>
<td></td>
<td>Cytochrome oxidase subunits I and II</td>
</tr>
<tr>
<td></td>
<td>Mitochondrial precursor transcript</td>
</tr>
<tr>
<td>Membrane estrogen-receptor–mediated activation of second-messenger and protein-kinase signaling78,79</td>
<td>Levels of cAMP and cAMP-responsive genes80</td>
</tr>
<tr>
<td></td>
<td>MAPK family81,82</td>
</tr>
<tr>
<td></td>
<td>ERK1 and ERK283</td>
</tr>
<tr>
<td></td>
<td>G-protein activation84</td>
</tr>
<tr>
<td></td>
<td>Inhibition of JNK and stimulation of ERK activity in association with inhibition85</td>
</tr>
</tbody>
</table>

* EGF denotes epidermal growth factor, IGF-1 insulin-like growth factor 1, MAPK mitogen-activated protein kinase, PI3K phosphoinositide 3 kinase, ERK extracellular signal-activated protein kinase, and JNK c-jun N-terminal kinase.
The mechanisms through which estrogens contribute to each phase of the carcinogenic process (initiation, promotion, and progression) are complex. The evidence suggests that the participation of genotoxic estrogen metabolites and estrogen-recep-
tor–mediated genomic and nongenomic signaling that affect cell proliferation and apoptosis in mammary tissue. The extent to which these two pathways contribute to estrogen-mediated carcinogenesis and the ways by which genetic polymorphisms and environmental factors modify the effects of these pathways require further exploration. Even so, knowledge of the central role of estrogen in breast cancer has already led to the development of new preventive and therapeutic interventions that block receptor function or drastically reduce the levels of endogenous estrogen through the inhibition of its synthesis. The development of additional strategies on the basis of the inhibition of estrogen metabolism, inactivation of the reactive quinones, and specific inhibition of membrane estrogen-receptor–activated second-messenger pathways will probably lead to the availability of additional effective intervention approaches.

Supported by grants (CA36701 and CA77550, to Dr. Yager, and CA88843, to Dr. Davidson) from the National Institutes of Health, from the Breast Cancer Research Foundation and the Avon Foundation (to Dr. Davidson).

No potential conflict of interest relevant to this article was reported.

References


111. Goss PE, Ingle JN, Martinho S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in re-
Mechanisms of Disease


Copyright © 2006 Massachusetts Medical Society.